Literature DB >> 7344416

Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil.

I Nordgren, E Bengtsson, B Holmstedt, B M Pettersson.   

Abstract

A method for the simultaneous quantitation of metrifonate (0,0-dimethyl-(1-hydroxy-2,2,2-trichloroethyl)-phosphonate) and dichlorvos (2,2-dichlorovinyl dimethyl phosphate, DDVP) in human blood has been worked out. It is based upon multiple labelling of the compounds with deuterium and gas phase analysis using the mass spectrometer as a selective detector. The amount of DDVP in plasma is about 1% of the amount of metrifonate. In erythrocytes the corresponding amount of DDVP is 0.5% or less of metrifonate. Both compounds reach peak levels in blood within two hours after oral dosing and are detectable for at least eight hours. Cholinesterase activity in plasma reaches zero levels within 15 min. and remains inhibited for more than eight hours. Red blood cell cholinesterase is inhibited only 60-80%. According to kinetic calculations, clearance of metrifonate occurs primarily via dichlorvos. If dichlorvos is the only active component, which in all likelihood it is, it's slow release may be important in the schistosomicidal effect. Clinical data in seven metrifonate treated patients revealed that mild vertigo subsiding in a few hours was the most common side effect.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7344416     DOI: 10.1111/j.1600-0773.1981.tb03256.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  12 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 2.  Acetylcholinesterase of Schistosoma mansoni--functional correlates. Contributed in honor of Professor Hans Neurath's 90th birthday.

Authors:  R Arnon; I Silman; R Tarrab-Hazdai
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

Review 3.  Metrifonate.

Authors:  H M Lamb; D Faulds
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 4.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

6.  A simplified dosage schedule of metrifonate in the treatment of Schistosoma haematobium infection in Somalia.

Authors:  Y Aden-Abdi; L L Gustafsson; S A Elmi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Incident diabetes and pesticide exposure among licensed pesticide applicators: Agricultural Health Study, 1993-2003.

Authors:  M P Montgomery; F Kamel; T M Saldana; M C R Alavanja; D P Sandler
Journal:  Am J Epidemiol       Date:  2008-03-14       Impact factor: 4.897

8.  Distribution and placental transfer of trichlorfon in guinea pigs.

Authors:  G N Berge; I Nafstad
Journal:  Arch Toxicol       Date:  1986-05       Impact factor: 5.153

9.  AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.

Authors:  Marja Van Kampen; Karin Selbach; Renate Schneider; Elleonore Schiegel; Frank Boess; Rudy Schreiber
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

10.  Metrifonate effects on acetylcholine and biogenic amines in rat cortex.

Authors:  F Mori; G Cuadra; E Giacobini
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.